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D
espite its low incidence, 
retinoblastoma has attracted 
the great interest of not just 
pediatric oncologists, but also cancer 
biologists and oncologists who treat 
cancer in adults. Retinoblastoma 
reminds us that rare conditions with 
a hereditary component may be rare 
for a reason—the genes associated 
with them are important biologically. 
It is hardly surprising then that 
retinoblastoma continues to be a 
subject of interest to a large group of 
clinicians and scientists, as described 
by Dyer and colleagues in this issue of 
PLoS Medicine [1].
A Success Story
For the pediatric oncologist, the 
treatment of retinoblastoma has been 
one of the success stories of the past 
century, with a cure rate in the United 
States of 95% [2,3]. The clinicians’ 
concerns are now those children who 
do not survive, those who lose one 
or both eyes, and those who sustain 
delayed effects, including late death 
from a second cancer.
For cancer biologists, including 
myself, retinoblastoma has been a 
model for guiding our understanding 
of cancer genes. For me, it was a 
simplifying condition to study: a child 
could inherit a mutated gene that 
could produce a cancer even in a 
newborn, so such a gene must surely 
be important for cancer research. 
Indeed, the retinoblastoma gene RB1 
was the ﬁ  rst hereditary cancer gene 
and the ﬁ  rst tumor-suppressor gene 
to be cloned, and it has proven to be 
biologically important. The RB protein 
was shown to be a principal controller 
of the cell cycle in all human tissues. 
Furthermore, RB protein is inactivated 
by speciﬁ  c proteins produced by DNA 
tumor viruses, thereby demonstrating 
the oncogenic mode of action of 
their already known transforming 
factors. Showing this inactivation 
was, historically, critically important 
in resolving conﬂ  icting notions of 
viral versus genetic oncogenesis, just 
as the RNA tumor viruses directed 
investigators to proto-oncogenes.
Lessons for Other Cancers
Pediatric oncologists treating 
retinoblastoma continue to address 
problems of general interest to all 
oncologists. The discovery that RB1 
is a gene whose mutations can also 
predispose a person to sarcomas, which 
in turn can be initiated by ionizing 
radiation, has implications for other 
cancers, and pediatrics has led the way 
in modifying therapy to reduce the 
probability of such a consequence. 
The use of chemotherapy and focal 
treatment to reduce the need for 
bilateral enucleation (surgical removal 
of the eye from its orbit) and/or 
radiation provides another example 
of the amelioration of late effects. The 
incidences of both late mortality and 
blindness have been reduced.
Following the cloning of RB1, more 
than 40 hereditary cancer genes have 
been cloned, including the gene 
for familial adenomatous polyposis, 
APC. As with retinoblastoma, APC was 
shown to be somatically mutant in a 
large majority of nonhereditary colon 
cancers, thereby stimulating interest in 
the study of hereditary cancer for the 
purpose of illuminating the biology 
of all cancer. However, the common 
carcinomas are often preceded by 
benign precursor lesions, such as the 
colonic polyp, whose diagnosis and 
removal can be an important preventive 
measure, especially since there is often 
a considerable time interval between 
formation of the precursor and its 
malignant transformation.
Making Further Clinical Progress
Further clinical progress may depend 
on a deeper understanding of the 
mechanisms of transformation in cells 
with defective or absent RB protein. 
Still unanswered is the following 
question: why is RB1 a retinoblastoma 
gene? Knowledge of control of the cell 
cycle by RB protein does not explain 
the protein’s tissue speciﬁ  city or its 
importance for retinal development. 
Following the cloning of RB1, knockout 
mice were produced, enabling the 
production and study of homozygotes. 
The homozygous state is lethal to 
embryos, with developmental defects 
in multiple tissues, including the brain. 
If heterozygous humans did not also 
develop tumors, we might know RB1 
as a recessive, developmental, lethal 
gene. Can the developmental defects 
be explained by what is known about 
control of the cell cycle by RB protein? 
Apparently not. 
Now Dyer and colleagues, and other 
researchers [1] have discovered that RB 
protein interacts with other proteins 
that have separate developmental roles. 
A mutant retinal tissue progenitor 
cell is apparently arrested along its 
developmental pathway, and the 
arrested daughter cells continue to 
divide indeﬁ  nitely. This discovery has 
stimulated a search for separate agents 
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affecting either differentiation or 
development, one such combination 
being carboplatin and topotecan.
Even if a cure is usually accomplished 
with the application of current 
knowledge, there remain two 
problems. The ﬁ  rst problem is the 
lethal progression of a few cases. 
The second is the problem of late 
effects, especially the difﬁ  cult effect 
of second cancers in hereditary cases. 
Since these problems are also issues 
for other cancers, retinoblastoma 
assumes a special importance, with a 
seemingly better opportunity to identify 
secondary events in tumors. The 
rapid growth of retinoblastoma may 
facilitate recognition of rate-limiting 
steps in progression, especially with the 
availability of a good animal model. 
Since RB1 and other functionally 
related genes are somatically mutant in 
so many cancers, study of them should 
be widely relevant. 
A New Role for Pediatric 
Oncologists?
Can pediatric oncologists participate 
directly in reducing the burden of 
cancer in adults? Is there a possibility 
of prevention? I have serious doubts 
that much could be done to prevent 
cancer in children, but intervention 
may be feasible in hereditary 
conditions that cause cancer in adults. 
Thus, both familial adenomatous 
polyposis and neuroﬁ  bromatosis type 
1 have incidences more than twice 
that of retinoblastoma. Successful 
intervention in childhood might 
possibly lead to delay or prevention 
of later malignancies. Any success 
would also be relevant to prevention 
of nonhereditary cancer, which would 
be especially important for colon 
cancer since most cases involve somatic 
mutations in the APC gene. Pediatric 
oncologists may ﬁ  nd themselves in a 
new leadership role.  
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